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Abstract 
Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid that occurs naturally in the mammalian 
brain and that is prescribed as a medication against narcolepsy or used as a drug of abuse. Particularly, 
its use as a knock-out drug in cases of drug facilitated crimes is of major importance in forensic 
toxicology. Because of its rapid metabolism and resulting narrow detection windows (<12 h in urine), 
detection of GHB remains challenging. Thus, there is an urgent call for new markers to improve the 
reliable detection of GHB use. In the framework of a randomized, placebo-controlled, crossover study 
in 20 healthy male volunteers, urine samples obtained 4.5 hours post-administration were submitted to 
untargeted mass spectrometry (MS, QTOF) analysis to identify possible new markers of GHB intake. 
MS data from four different analytical methods (reversed phase and hydrophilic interaction liquid 
chromatography; positive and negative electrospray ionization) were filtered for significantly changed 
features applying uni- and multivariate statistics. From the resulting 42 compounds of interest, eight 
were finally identified including conjugates of GHB with carnitine, glutamate, and glycine as well as 
the endogenous compounds glycolate and succinylcarnitine. While GHB conjugates were only 
detectable in the GHB, but not in the placebo group, glycolate and succinylcarnitine were present in 
both groups albeit significantly increased through GHB intake. Untargeted metabolomics proved as a 
suitable tool for the non-hypothesis driven identification of new GHB markers. However, more 
studies on actual concentrations, detection windows, and stability will be necessary to assess the 
suitability of these markers for routine application. 
 
Keywords: GHB, carnitine, untargeted metabolomics, placebo-controlled 
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Introduction 
Gamma-hydroxybutyrate (GHB) is a short-chain fatty acid that occurs naturally 
1, 2
, but is also 
exogenous applied as a drug of abuse (DOA) or as a prescription medication. Clinically, the drug is 
internationally approved for the treatment of narcolepsy with cataplexy, as it improves sleep 
impairments and daytime sleepiness in these patients, and significantly reduces cataplectic attacks
3
. 
GHB and its precursors γ-butyrolactone (GBL) and 1,4-butanediol are also consumed/abused 
recreationally as DOAs. In forensic toxicology, particularly their use as so-called date rape or knock-
out drug in cases of drug facilitated crimes (DFC) or drug facilitated sexual assaults (DFSA) is of 
importance
4, 5
.  
In vivo, GHB is rapidly converted to succinic semialdehyde followed by subsequent oxidation to 
succinate, an intermediate of the Krebs cycle
6
. Further, GHB is catabolized by processes that include 
direct β-oxidation resulting in acetyl-CoA and glycolate and α-oxidation forming 3-
hydroxypropionyl-CoA
7, 8
. Recently, formation of phase II metabolites of GHB, namely GHB-
glucuronide and GHB-sulfate have been described
9, 10
. An overview of the main pathways involved in 
GHB catabolism/metabolism is depicted in Fig. 1. Due to its rapid metabolism and therefrom 
resulting narrow detection windows of only up to 6 hours in plasma and less than 12 hours in urine
11, 
12
, detection of GHB, particularly in DFSA cases, remains challenging. Particularly discrimination 
between endogenous and exogenous GHB is complicated, especially in those samples with low 
concentrations. Numerous authors recommend cut-offs to facilitate such a decision. However, a 
standard procedure has not yet been specified
4
. 
Current research interest focuses on new metabolites or new methodologies to prolong the detection 
window after GHB intake/administration and to improve the differentiation between endogenous 
levels and exogenous administration. The phase II metabolites GHB-glucuronide and GHB-sulfate 
have been evaluated for that purpose, assuming phase II conjugates to have longer half-lives than the 
parent drug
9, 10
. While both metabolites could be detected, comprehensive pharmacokinetic data on 
their elimination after controlled GHB administration are still missing. Petersen et al. found large 
inter-individual differences in reference ranges of endogenous GHB-glucuronide concentrations in 
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urine, but did not measure any authentic GHB positive cases
10
. Mehling et al. could demonstrate 
increased GHB-glucuronide levels in urine samples of three subjects, however, the concentrations 
were generally not higher than endogenous concentrations measured in a control group
13
. Hanisch et 
al. suggested the existence of a sulfonated GHB metabolite, GHB-sulfate, and were able to detect it in 
authentic urine samples
9
. But again, further studies on GHB-sulfate also indicated that the large inter-
individual variability of concentrations found in a reference population makes GHB-sulfate itself 
unsuitable to prolong the detection times of GHB applications
14
. So far, neither GHB-glucuronide nor 
GHB-sulfate proved suitable to ultimately confirm exogenous GHB consumption or prolong its 
detection window
13, 14
. A completely new and interesting strategy has been recently described by 
Mehling et al., trying to assess differential gene expressions after GHB intake to identify potential 
biomarkers for the detection of GHB intake. However, because of the low statistical power of the 
small sample size, alterations in gene expression relating to GHB intake could not be confirmed to a 
forensically sufficient degree
15
. Thus, the identification of novel biomarkers of GHB consumption 
remains of highest interest. 
Metabolomics research focuses on high-throughput identification of a multitude of small molecular 
weight molecules in one single sample. Mapping the biochemical changes after DOA exposure may 
complement traditional approaches by revealing potential biomarkers of organ toxicity, discovering 
new metabolites in a time- and dose-dependent manner and different pharmacodynamic targets. This 
approach can also help by giving insights about the pathways implicated in the mechanism of drug 
action, adverse effects and variability of the drug response
16
. A few metabolomic studies have been 
performed in order to further evaluate the underlying mechanisms of GHB’s pharmacological action17, 
18
 or to finally find useful biomarkers of its consumption
14, 18, 19
. For example, Luca et al. found up to 
sevenfold higher levels of glycolate – originating form β-oxidation of GHB - in brain and liver of 
mice
18
. Also Palomino-Schätzlein et al. observed significant increases in glycolate as well as 
succinate in urine following controlled administration of GHB to humans using nuclear magnetic 
resonance (NMR)-based metabolomics
19
. Piper et al. applied mass spectrometry (MS)-based 
metabolomics while searching for endogenous urinary metabolites potentially correlating with the 
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urinary excretion of GHB-sulfate and GHB-glucuronide in order to find a suitable marker to 
normalize urinary concentrations
14
. 
Although initial attempts have recently been made to find potential biomarkers of GHB, forensic 
toxicology is still in need for a reliable marker to confirm the consumption of GHB and its substitutes, 
particularly over longer time frames. Therefore, the exclusive aim of the current study was to identify 
possible new markers of GHB intake by evaluating urine samples obtained in the framework of a 
randomized, placebo-controlled, crossover study of GHB administration to 20 healthy male volunteers 
who took the study medication at night in the middle of a sleep episode. Urine was subsequently 
sampled after awakening in the morning. While it is obvious that the GHB study design was not 
suitable to find a marker that can prolong the time of detection, the relatively short time between 
application of GHB and the urine sampling (4.5 h) ensured the presence of the parent compound and 
the possibility to find any new markers for GHB intake. Thus, long time detectability was not part of 
the present study. The new markers should be identified as part of a comprehensive MS-based, 
untargeted metabolomics approach. The further investigation of other metabolomic changes after 
GHB intake was not part of the current study.  
 
Materials and Methods 
Participants 
The study followed a randomized, balanced, double-blinded placebo-controlled crossover design as 
described in detail elsewhere (Dornbierer DA, Boxler M, Voegel CD, Stucky B, Steuer AE, Binz TM, 
Baumgartner MR, Baur DM, Quednow BB, Kraemer T, Seifritz E, Landolt HP, Bosch OG. Noctural 
gamma-hydroxybutyrate reduces cortisol awakening response and morning tryptophan catabolites 
(TRYCATs) in healthy volunteers, under review) and was approved by the Cantonal Ethics 
Committee of Zurich as well as the Swissmedic. The study was registered at ClinicalTrials.gov 
(NCT02342366). All participants were instructed about potential risks concerning the administered 
substance and provided written informed consent. They received a monetary compensation for the 
completion of the study. 
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Two experimental nights per session were separated by a washout phase of seven days. Each session 
consisted out of three nights: an adaptation night, an experimental night – where patients either 
received 50 mg/kg bodyweight of sodium oxybate (Xyrem®) or placebo – and a follow-up night. 
Twenty healthy, male volunteers (mean age 25.8±2.45 years) participated in the study. Following 
criteria were required for inclusion: (i.) male sex to avoid the potential impact of menstrual cycle on 
blood chemical variables, (ii.) age within the range of 18 to 30 years, (iii.) absence of any somatic or 
psychiatric disorders, (iv.) no first-degree relatives with a history of psychiatric disorders, (v.) non-
smoking, (vi.) without a history of drug abuse (lifetime use >5 occasions, with exception of 
occasional cannabis use). None of the participants reported previous experiences with GHB in their 
life. Participants had to restrain from illegal drugs for two weeks and from caffeine for one week prior 
to the first and until the second experimental night. No alcohol was allowed 24 h before each 
experimental night. 
 
Procedure 
GHB was administered at the beginning of the second half (2:30 am) of the experimental night. 
Therefore, subjects were woken up at 2:30 am and each subject received 50 mg/kg of GHB (Xyrem®) 
dissolved in 2 dl of orange juice anda placebo (each participant underwent two session, one with 
placebo, one with GHB, see section Participants), matched in appearance and taste. After that, 
subjects were allowed to return to sleep. The used dose represents the maximal starting dose used for 
the treatment of narcolepsy (compendium.ch). Early morning urine was collected after the adaptation 
night and the experimental night (7:00 am) and stored at -80 °C till analysis (maximum of 24 months).  
 
Chemicals and Reagents 
GHB was obtained from Lipomed (Arlesheim, Switzerland) and GHB-glucuronide from Reseachem 
(Burgdorf, Switzerland). 1-Methylhistidine, adenine, adenosine, arginine, azelaic acid, 
butyrylcarnitine, carnitine, chenodeoxycholic acid, cholic acid, citrulline, cortisol, cortisone, 
creatinine, deoxycholic acid, glutaric acid, glycolic acid, glycocholic acid, hippuric acid, inosine, 
isoleucine, leucine, L-pyroglutamic acid, methionine, methylmalonic acid, mevalonolactone, N,N-
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dimethylglycine, nicotinic acid, p-aminobenzoic acid, phenylalanine, proline, raffinose, riboflavin, 
taurine, taurocholic acid, tryptophan, and uracil were purchased from Sigma-Aldrich (Buchs, 
Switzerland). Deuterated and heavy-labeled internal standards (IS) adenosine ribose-D1, arginine-
13
C6, 
caffeine 3-methyl-
13
C, carnitine trimethyl-D9, creatinine N-methyl-D3, deoxycholic acid-D4, D-
fructose 
13
C, glycine-
13
C2, glycocholic acid-D4, hippuric acid 
15
N, kynurenine-D4, leucine-D10, lysine-
D4, phenylalanine-D1, proline 
15
N, serine-D3, tryptophan-D5 and uric acid-
15
N2 were purchased from 
Cambridge isotope laboratories, which were delivered by ReseaChem Life Science (Burgdorf, 
Switzerland) or Sigma-Aldrich (Buchs, Switzerland). Water, acetonitrile (ACN), methanol (MeOH) 
of HPLC grade were obtained from Fluka (Buchs, Switzerland). All other chemicals used were from 
Merck (Zug, Switzerland) and of the highest grade available.  
 
Sample preparation 
Urine samples of the experimental nights after placebo and GHB intake of 19 participants (sample of 
one participant was unavailable) were thawed at room temperature and vortexed for 20 seconds. Forty 
μL of the IS mix (adenosine ribose-D1 15 µmol/L, arginine-
13
C6 300 µmol/L, caffeine 3-methyl-
13
C 
200 µmol/L, carnitine trimethyl-D9 100 µmol/L, creatinine N-methyl-D3 500 µmol/L, deoxycholic 
acid-D4 1.8 µmol/L, D-fructose 
13
C 120 µmol/L, glycine-
13
C2 800 µmol/L, glycocholic acid-D4 150 
µmol/L, hippuric acid 
15
N 500 µmol/L, kynurenine-D4 8 µmol/L, leucine-D10 300 µmol/L, lysine-D4 
700 µmol/L, phenylalanine-D1 300 µmol/L, proline 
15
N 700 µmol/L, serine-D3 450 µmol/L, 
tryptophan-D5 250 µmol/L and uric acid-
15
N2 500 µmol/L)
20
 was placed into autosampler filter vials 
(0.45 µm PTFE, Thomson Instrument company, California, USA) and 200 μL of urine sample were 
added. Depending on the acquisition method either 200 μL of a 1:1 (v/v) mixture of eluents A and B 
(for measurement on the HSST column) or C and D (for measurement on the HILIC column,see 
below) was added. After mixing, the filter vials were carefully closed with a filter plunger and were 
either analyzed directly as described below or stored at -20 °C until analysis. A mix of all urine 
samples (200 µl each) of the clinical study was prepared (pooled sample) and prepared as described 
above.  
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UHPLC-HRMS 
In total 38 samples (19 participants, 2 sessions) were subjected to MS measurements in randomized 
order on a Thermo Fischer Ultimate 3000 UHPLC system (Thermo Fischer Scientific, San Jose, CA) 
coupled to a high-resolution (HR) TOF instrument system (TripleTOF 6600, Sciex, Concord, Ontario, 
Canada). Mobile phases A and B consisted of 10 mM ammonium formate with 0.1 % (v/v) formic 
acid in water and 0.1 % (v/v) formic acid in MeOH, respectively. Mobile phases C and D were 25 
mM ammonium acetate and 0.1 % (v/v) acetic acid in water and 0.1 % (v/v) acetic acid in ACN, 
respectively.  
Two different columns – reversed phase and hydrophilic interaction liquid chromatography (HILIC) 
were used for chromatographic separation. A Waters (Baden-Daettwil, Switzerland) XSelect HSST 
RP-C18 column (150 mm x 2.1 mm, 2.5 µm particle size) was applied with the following gradient: 1 
min 100% A; 1-15 min 100% B; 15-18 min 100% and then decreased to start conditions and re-
equilibration for 2 min. Flow rate increased after 15 min to 0.7 ml/min. Further a Merck SeQuant ZIC 
HILIC column (150 mm x 2.1 mm, 3.5 µm particle size) using the following gradient: 1 min 95% D; 
1-10 min decrease to 40% D; 10-12 min  decrease to 10% D; 12-13 min 10% D; and then increase to 
start conditions and re-equilibration for 2 min was used. The column oven was set to 40 °C and 
injection volume was 1 µl for all samples. 
High resolution mass spectra (MS) and MS/MS data were acquired by two methods: TOF MS only 
and information dependent data acquisition (IDA) in positive and negative ionization mode. MS 
analysis was performed with a DuoSpray ion source at a resolving power (full width at half-maximum 
at m/z 400) of 30’000 in MS and 30’000 in MS2 (high-resolution mode) or 15’000 (high-sensitivity 
mode) in positive ionization mode. Automatic calibration was obtained every fifth sample injections 
using atmospheric-pressure chemical ionization (APCI) positive calibration solution (Sciex) in the 
positive ionization mode and every three sample injections using APCI negative calibration solution 
(Sciex) in the negative ionization mode. The TOF MS method was composed of a TOF-MS scan over 
a mass range from m/z 50 to m/z 1000 (accumulation time 100 ms, collision energy (CE) 5 eV). 
Additionally, about 20% of the samples were measured in the IDA scan mode. The IDA method 
consisted of a TOF-MS scan over a mass range from m/z 50 to m/z 1000 (accumulation time 50 ms, 
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CE 5 eV). IDA experiments (accumulation time for each IDA experiment 100 ms, CE 35 eV with a 
CE spread of 15 eV) were performed after dynamic background subtraction on the four most intense 
ions with an intensity threshold above 100 counts per second (cps) and exclusion time of 5 s (half 
peak width) after two occurrences in high sensitivity mode.  
A system suitability test (SST) containing 1-methylhistidine, adenine, adenosine, arginine, azelaic 
acid, chenodeoxycholic acid, cholic acid, citrulline, cortisol, cortisone, creatinine, deoxycholic acid, 
glutaric acid, glycocholic acid, hippuric acid, inosine, isoleucine, leucine, L-pyroglutamic acid, 
methionine, methylmalonic acid, mevalonolactone, N,N-dimethylglycine, nicotinic acid, p-
aminobenzoic acid, phenylalanine, proline, raffinose, riboflavin, taurine, taurocholic acid, tryptophan 
and uracil (concentration 10 μg/ml each) was measured after every fifth sample. The SST was 
checked for reproducibility of the data by retention time (RT) shifts and peak area comparison using 
MultiQuant V 2.1 (Sciex). Further, a pooled sample was additionally measured after every fifth 
sample. 
 
Targeted data evaluation for GHB, GHB-glucuronide, and GHB-sulfate 
Targeted analysis from the untargeted data set on GHB and its phase II metabolites GHB-glucuronide 
and GHB-sulfate was performed by obtaining peak areas using MultiQuant 2.1 (Sciex). Analyte peak 
areas were normalized to creatinine (determined by the Jaffe reaction on an Indiko Plus device, 
Thermo Scientific, Braunschweig, Germany) of each urine sample. Statistical comparison by paired t-
tests (p < 0.05) was performed in GraphPad Prism 7 (GraphPad Software, CA, USA). 
 
Feature selection/statistical evaluation 
Progenesis QI (Waters Corp, Milford, USA) was used for data-preprocessing, alignment, 
deconvolution, peak picking, initial data normalization and filtering on TOF data only. Data files of 
the IDA scan mode were incorporated in the software for identification purposes only. Via automatic 
processing, a reference run was picked based on its similarity to all the other runs and used as a 
reference for retention time alignment. Peak picking parameters were as follows: automatic sensitivity 
method, sensitivity value 3, no minimum peak width and no retention time limits. Features were 
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automatically deconvoluted based on the same retention time and ion masses that differ by an amount 
equal to the mass difference between 2 experiment adducts. All samples were normalized to the 
feature identified as creatinine in each method. All four data sets (HSST ESI
+
, HSST ESI
-
, HILIC 
ESI
+
, HILIC ESI
-
) were initially filtered for features with MS/MS information from respective IDA 
files available and an abundance > 1000 cps in positive and > 500 cps in negative mode, respectively.  
Paired t-test (p < 0.05) and partial least square discriminant analysis (PLS-DA) was applied on log-
transformed and auto-scaled data after initial data filtering by median intensity values in 
MetaboAnalyst 4.0
21
. 
 
Compound identification 
Significant features were searched on the MS and MS/MS level against an in-house database, national 
institute of standards and technologies (NIST) and Chemspider in Peakview 2.2 as well as in the 
online databases METLIN (https://metlin.scripps.edu) and the human metabolome database
22
 in 
Progenesis QI. Confirmation of identity was performed by library search matching (library fit search 
score, > 90%) of the accurate mass of precursor and fragment ions and retention time values to 
authentic standards if available. 
Final identification results were classified on the different levels of identification confidence 
suggested by the metabolomics standard initiative (MSI)
23
: level 1 provides identified compounds and 
uses two or more measured orthogonal parameters (e.g. retention time and mass spectrum) of an 
authentic chemical standard analyzed under the identical analytical conditions that matches the 
metabolite present in the sample. Level 2 provides putatively characterized compounds and 
identification is based on physicochemical properties and/or similarities with mass spectra of public or 
commercial libraries. Level 3 provides putatively characterized compound classes by spectral 
similarities to known compounds of a chemical class or based upon physicochemical properties of a 
chemical class.  
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Authentic GHB urine samples 
Thirty routine urine samples (n=10 GHB positive, n=20 control samples) send to the author’s lab by 
police or state attorneys were reanalyzed anonymized in full conformance with Swiss laws (statement 
of Cantonal Ethics Board of the Canton of Zurich: BASEC-Nr. Req-2017-00946). GHB had been 
tested during case work in all samples using a GHB enzymatic assay (cut-off 40 mg/L, in-house 
validated) from Bühlmann (Schönenbuch, Switzerland) on an Indiko Plus device (Thermo Scientific, 
Braunschweig, Germany). Positive findings had been confirmed by a routine gas chromatography 
(GC)-MS analysis (liquid-liquid extraction with ethylacetate; derivatization with N-Methyl-N-
(trimethylsilyl) trifluoroacetamide; GHB-d6 as IS). Creatinine was determined by the Jaffe reaction 
on an Indiko Plus device. Samples were initially assigned as GHB positive if the immunoassay result 
was > 40 mg/L and presence of GHB was confirmed by GC-MS (measured urine concentration range: 
76 – 12000 mg/L). Targeted analysis on previously identified markers was performed in MultiQuant 
2.1 (Sciex).  
 
Results and Discussion 
Although initial attempts have recently been made to find potential biomarkers for GHB, forensic 
toxicology is still in need for a reliable marker other than GHB itself to confirm the consumption of 
GHB particularly over longer time-frames. MS-based, untargeted metabolome analysis is an 
interesting emerging analytical technique for biomarker research. The current study strictly focuses on 
the identification of potential new biomarkers for GHB showing large differences between placebo 
and GHB groups from a placebo-controlled crossover study.  
 
Analytical procedure 
A universal LC-HRMS method was selected that is typically applied in metabolomics studies
24, 25
. 
Two different chromatographic systems – reversed phase (HSST) and HILIC – in both positive and 
negative ionization mode were chosen to cover as many small molecules as possible. The applied 
screening method has been extensively examined recently on analyte selection, detectability and 
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sensitivity 
20
 and was already successfully applied to other untargeted and targeted studies of the 
metabolome
26-28
. For peak picking and deconvolution, measurements were only performed in TOF-
MS mode, while additional runs were performed after IDA MS/MS acquisition for identification. 
Analytical performance was monitored over each whole batch through regular analysis of SST and 
pooled samples. Mean coefficient of variation (CV) of the peak area of all SST compounds for the 
four methods were 7.5 +/- 1.5 for HSST ESI
+
, 14 +/- 4.3 for HSST ESI
-
, 33+/- 18 for HILIC ESI
+
, and 
16 +/- 8.8 for HILIC ESI
-
, respectively and were overall comparable to former studies
28
. Pooled 
samples’ CVs were higher when calculated for all detected features. However, the large majority of 
all features were of very low abundance. In the current study, only features with an abundance of at 
least 1000 cps in positive and 500 cps in negative mode were further evaluated. For these features, 
variation was < 30% for more than 80% of all features. Overall, all experiments were reproducible in 
terms of peak intensity and retention time continuity and were therefore used for the analysis of the 
data. Additionally, all samples were analyzed in random order to avoid systematic effects resulting 
from varying instrument performance during runtime of the batch.  
 
Targeted analysis of GHB, GHB-glucuronide and GHB-sulfate 
Prior to untargeted data evaluation, targeted analysis on GHB and its previously described metabolites 
GHB-glucuronide and GHB-sulfate was performed from the untargeted data acquisition. It has to be 
mentioned that the applied analytical methods had not been optimized for GHB or its metabolites. 
Nevertheless, GHB as well as its glucuronide and sulfate conjugate could be detected in all urine 
samples of the GHB group using HILIC chromatography and negative ionization. Hanisch et al were 
unable to reproducibly measure GHB-sulfate in negative mode
9
 which was not observed in the present 
work. The chromatography for the three analytes is given in the supplementary information Fig. S1. 
Although GHB is only shortly retained, it was sufficiently separated from two isomers (presumably α- 
and β-hydroxybutyric acid). Identity of GHB and GHB-glucuronide was confirmed based on accurate 
mass, MS/MS and retention time comparison to reference material. GHB-sulfate has not been 
commercially available, but could be nevertheless identified by its accurate mass and interpretation of 
its MS/MS spectrum. The MS/MS spectra are given in Fig. S2. No actual quantification was 
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performed, as samples were only analyzed in the untargeted metabolome method. Therefore, all 
results are given on analyte peak area over creatinine ratios. Results for the comparison between 
placebo and GHB administration are given in Fig. 2 for the group as a whole and additionally for each 
single subject in the supplementary information Fig. S3. As expected, GHB significantly increased 
after GHB administration. On the contrary, no significant differences between treatments could be 
observed for GHB-glucuronide and GHB-sulfate. Systematic studies on the pharmacokinetics of GHB 
phase II metabolites under controlled conditions are scarce and limited to small sample sizes (n=3) or 
authentic (and thus not controlled) samples only. While increases in GHB-glucuronide and GHB-
sulfate were sometimes observed
13, 14
, the concentrations were generally not different from 
endogenous levels. Tittarelli et al. also could not observe significant differences of GHB-glucuronide 
concentrations in plasma to control patients
29
. 
In the present study, individual subjects also showed trends for higher GHB-glucuronide and/or 
higher GHB-sulfate levels, but overall the effect was negligible. We further confirmed our findings 
through additional analysis of authentic samples, which confirmed the study results regarding GHB-
glucuronide and GHB-sulfate (Fig. S4). The reason for GHB-glucuronide and GHB-sulfate being 
unaffected by treatments remains unclear. It appears possible, that the responsible enzymes, UDP-
glucuronyltransferases and sulfotransferases, might be already saturated by endogenous GHB 
concentrations, although no data on involved isoenzymes, respective affinities (Km) and enzyme 
capacities (Vmax) are available. As already proposed by others, our data propose that GHB-
glucuronide and GHB-sulfate are not suitable to monitor GHB consumption
13, 14
.  
 
Untargeted metabolomics analysis: selection of potential interesting features 
Prior to feature filtering and selection, normalization to creatinine was applied as typically used for 
urine specimens. Typical metabolomics analysis results in large amounts of data. To improve data 
handling, initial analysis focused only on features with MS/MS data from IDA experiments available, 
resulting in 194, 111, 55 and 101 picked features for HSST ESI
+
, HSST ESI
-
, HILIC ESI
+
 and HILIC 
ESI
-
, respectively.  
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Further advanced statistical evaluation of the data was performed with MetaboAnalyst
30
. Data 
reduction by median should further remove features close to baseline levels which will be unsuitable 
as reliable biomarker. The data were further log transformed and auto-scaling (mean-centering and 
division by the standard deviation of each variable) was applied. With this, uniform distribution of the 
data was achieved, as also described previously
27, 28
  
Features showing significant differences in paired t-test analysis were initially considered of particular 
interest for further identification. Additionally, features showing the highest variable importance 
parameters (VIPs) scores per method (first 15 each) determined in PLS-DA analysis were additionally 
considered. The higher the VIP score, the higher the contribution of a certain feature to separate 
placebo from GHB intake. Those features with analyte peak area/creatinine peak area intensity < 1000 
cps ESI
+
; < 500 cps ESI
-
 were omitted, as they had large CVs and were unlikely to provide 
reproducible results. 
Some features were detected under more than one condition, e.g., compound 8, that was detected both 
in HSST ESI
+
 and HILIC ESI
+
 or compound 14 that was detected in HSST ESI
+
 and ESI
-
. These 
features were combined to one single compound. In the end of the feature selection process, 42 
compounds fulfilled the described criteria and are given in Table 1, arranged according to their 
median fold-changes between placebo and GHB group. GHB itself (compound 7) was identified 
applying the described feature selection workflow proving its general applicability to pick features of 
interest. As already expected from the targeted data analysis, neither GHB-glucuronide nor GHB-
sulfate made it to that list due to missing significant differences between placebo and GHB group.  
 
Identification 
Out of the 42 total compounds that were subjected to MS/MS identification, eight could be tentatively 
identified and are presented in Table 1. The corresponding MS/MS spectra of four selected 
compounds (compound 1, 5, 8, and 38) are depicted in Fig. 3. Identification was based on accurate 
precursor mass (M+H
+ 
/ M-H
-
) and interpretation of accurate fragment ions calculating their 
molecular composition and respective ppm deviation. Identification levels were given according to the 
metabolomics standard initiative (MSI)
23
 in Table 1. For glycolate (compound 19) identity was 
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unambiguously confirmed by comparison of retention time and mass spectral information to a 
commercially available reference standard. Compound 1 and 5 were identified as amino acids 
conjugates of GHB, namely with glycine (compound 5) and glutamate (compound 1), while 
compound 8 represents the carnitine conjugate of GHB.  
Next to the eight (tentatively) identified compounds, no clear identifications were possible. One point 
that should be kept in mind is the presence of the adjuvant malic acid in the administered GHB 
preparation. Of course, malic acid itself or metabolites/conjugates of malic acid might massively 
differ between placebo and GHB group. So far, neither malic acid itself nor straight forward 
conjugations products could be identified.  
 
Newly identified GHB markers 
Different types of markers were identified as given exemplarily in Fig. 4. Additional information on 
changes of each single subject is given in Fig. S5. Identified compounds of particular interest will be 
discussed separately in the following subchapters. In general, some markers appear to be not present 
in control samples, but are formed in the presence of exogenous GHB, such as GHB-carnitine 
(compound 8), GHB amino acid conjugates (compounds 1 and 5), and several still unknown 
compounds (e.g., neutral mass 340.12). Such compounds are more likely direct derivatives or even 
metabolites of GHB and present the most promising candidates as markers for routine applications. 
As already discussed above, also derivatives of the adjuvant malic acid might appear only in the GHB 
group, but would be of no value in real cases, where GHB containing products other than Xyrem® are 
consumed. Therefore, only markers unambiguously identified are currently of interest. Several other 
compounds are present both in the control group and after GHB treatment albeit in different amounts. 
Typically, increased concentrations were observed, e.g., for glycolate (compound 19) and 
succinylcarnitine (compound 38), while only compound 42 showed concentration decreases.  
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GHB-Carnitine 
Compound 8 was identified as GHB-carnitine, the ester between GHB and L-carnitine. L-Carnitine 
(beta-hydroxy-gamma-trimethylaminobutyrate) is a small and highly polar zwitterionic molecule that 
plays a critical physiological role in β-oxidation and energy metabolism by translocating long chain 
fatty acids across the mitochondrial inner membrane
31-33
. Carnitine conjugation as a metabolic 
reaction for xenobiotics is rarely described
34
 and was initially shown for valproic acid 
35
. Considering 
the chemical structures of GHB and carnitine, theoretically formation of two isomers is possible: 
esterification between the hydroxy group and/or the carboxyl group of carnitine. Millington et al 
discussed in vivo formation of valproic acid carnitine to be catalyzed through the carnitine 
acyltransferase on the activated intermediate valproyl-CoA
35
. The structural similarity of GHB to 
butyric acid and endogenous occurring α- and β-hydroxy butyric acids makes its conjugation to 
carnitine via acyltransferase very likely. With an underlying enzymatic process, esterification between 
the carboxylic function of GHB with the beta-hydroxy group of carnitine in analogy to 
butyrylcarnitine or β-hydroxy butyrylcarnitine seems highly likely. This assumption is supported by 
the underlying mass spectra depicted in the Fig.S6. Comparable fragmentation pattern of the newly 
identified GHB-carnitine to β-hydroxy butyrylcarnitine and butyrylcarnitine were observed. The main 
fragment of m/z 85 results from a McLafferty rearrangement of the butyric acid side chain (carnitine) 
to m/z 144 followed by the loss of the trimethylamine moiety (-59)
36
. The m/z 103 results from the 
remaining GHB moiety. A major difference in abundance could be observed in the neutral loss of the 
carnitine backbone (-161) resulting in an m/z of 87 for GHB-carnitine and m/z 71 for butyrylcarnitine. 
In case of GHB-carnitine the resulting carbonyl-fragment can be stabilized by hydrogen bonds 
explaining its higher abundance. 
In contrast to GHB-glucuronide and GHB-sulfate, there seems to be no saturation effects of the 
carnitine acyltransferase as intake of GHB triggered high formation of this metabolite. However, 
currently little is known on the enzyme capacity towards GHB. Also non-enzymatic formation of 
GHB-carnitine seems possible. Considering its peak area, GHB carnitine appears as the most 
promising marker for GHB intake from the current data set. Of course, data on actual concentrations 
and particularly of detection windows are still missing and are desperately needed. In the present 
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study, only urine samples collected 4. 5 hours post GHB administration have been available, a time 
frame in which GHB itself can still be detected.  
Another advantage of GHB carnitine might be its ability to be detectable in positive ionization mode. 
Routine toxicological screening by LC-MS is often only performed following positive ionization and 
usually unable to detect GHB reliably. Integration of GHB-carnitine into routine LC-MS screening 
methods could allow for simultaneous detection of GHB consumption/administration in the very same 
run with common drug screening.  
 
GHB-Amino acid conjugates: GHB glutamate and GHB glycine 
Compound 1 and 5 were identified as level 3 identifications using HILIC chromatography and 
negative ionization as amino acid conjugates. Conjugation of xenobiotic carboxylic acids with 
endogenous amino acids has been shown to be an important metabolic pathway in the 
biotransformation of a number of compounds in a variety of species. The reaction involves the 
formation of an amide or peptide bond between the carboxyl group of the xenobiotic acid and the 
amino group of the endogenous compound. The conjugation reaction is generally accepted to be a 
two-step process starting with the same initial activation to acyl-CoA thioester as described for 
carnitine conjugation; followed by an acyl transfer to the amino group of an amino acid
37
. Since the 
initial observation of glycine conjugation to yield hippuric acid from benzoic acid, a number of 
alternative amino acids have been shown to be involved in amino acid conjugation. The amino acid 
utilized for conjugation is highly dependent on both the structure of the xenobiotic carboxylic acid 
and the species under investigation. The most frequently observed amino acid conjugates are those 
with glycine
37-39
. Compared to the detected GHB-carnitine, the abundance of GHB-glycine and 
particularly GHB-glutamate was much lower and might even be too low for routine applicability.  
 
Glycolate and succinylcarnitine 
While present in both treatment groups, glycolate and succinylcarnitine significantly increased in 
concentration due to GHB administration. Palomino-Schätzlein et al recently also observed significant 
concentration increases of glycolate and succinate in urine samples after controlled GHB 
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administration
19
. While succinate itself was not identified in the current study, an increase in 
succinylcarnitine, the carnitine conjugate of succinate was observed as a follow-up metabolite of 
succinate. Looking at the (endogenous) metabolism of GHB (Fig.1), elevated concentrations of 
compounds within these pathways seem reasonable after GHB intake. However, although significant 
differences (in paired samples) could be observed, it appears unlikely that under physiological 
conditions, taking inter-individual variations into account, an increase in glycolate, succinate or 
succinylcarnitine will not be sufficient to prove GHB intake.  
 
Identified marker in authentic routine samples 
A brief proof of concept experiment was performed monitoring the newly identified GHB markers in 
30 authentic samples (20 negative, 10 positive for GHB). Although the sample size was too small for 
reliable sensitivity and specificity calculation, a first proof of suitability of the markers was possible 
within a detection window where GHB itself is still detectable. As exemplified in Fig. 5 for GHB-
carnitine, it was undetectable in control samples, but present in 9 of 10 GHB positive specimens. 
Similarly, GHB-glutamate (compound 1) and GHB-glycine (compound 5) were only detected in the 
10 GHB positive specimens but in none of the controls. There was no correlation between urinary 
GHB concentration and presence or absence of the new GHB adducts. As the GHB samples were 
analyzed after anonymization – no further information of GHB dose or time since last intake was 
available. The selection bias in all samples was of course the analytically confirmed presence of GHB 
itself, pointing to recent GHB ingestion.  
 
Limitations of the study 
Our study had some limitations. Only men were allowed as study participants, while victims of DFSA 
cases typically are women. Urine samples were collected 4.5 hours post-administration, thus the 
potential of the identified markers to prolong GHB’s detection window cannot be concluded at date. 
So far, GHB-adducts with carnitine and amino acids could be only detected in a small number of 
cases were GHB itself was still present. In the controlled study design all participants received GHB 
in form of Xyrem®, while on the illegal market often GBL is consumed / administered. Considering 
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its rapid metabolism to GHB in the body, similar formation of adducts is expected nevertheless. In 
general, the applied GHB dose was rather low compared to doses administered in DFSA cases. 
Finally, the focus of the study was only on features with MS/MS data available from the screening 
approach, which might have excluded identification of other interesting markers simply not triggered 
by the applied MS methods. 
 
Conclusion 
Using untargeted metabolomics strategies, three new and promising GHB-metabolites, namely GHB-
carnitine, GHB-glutamate and GHB-glycine were identified for the first time. Furthermore, significant 
changes in concentrations of glycolate and succinylcarnitine were observed. More studies on actual 
concentrations, detection windows and stability will be necessary to assess the suitability of these 
markers for forensic routine applications. Untargeted metabolomics proved as a suitable tool for 
identification of new markers without prior knowledge on possible metabolic pathways. The 
identification of new GHB markers/metabolites might represent an important step to improve 
differentiation of endogenous from exogenous GHB and to prolong its detection window in cases of 
drug facilitated crimes.  
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Table 1: Identified features significantly changed by GHB ingestion. 
 
 
Analytical Feature name 
Measured 
m/z 
RT 
(min) 
Anova (p) 
VIP 
Score 
Fold 
change 
Formula (Tentative) identification 
Identification 
level 
23
 
Compound 01 HILIC ESI
-
 7.18_232.0830m/z 232.0830 7.2 1.8E
-14
 2.0 Infinity C9H15NO6 GHB-glutamate 3 
Compound 02 HILIC ESI
-
 5.35_250.9870m/z 250.9870 5.4 8.1E
-03
 1.1 Infinity 
   
Compound 03 HSST ESI
+
 4.00_259.0789m/z 259.0789 4.0 1.4E
-15
 2.7 Infinity 
   
Compound 04 HSST ESI
-
 3.99_235.0819m/z 235.0819 4.0 3.7E
-12
 1.9 900.8 
   
Compound 05 HILIC ESI
-
 5.70_160.0620m/z 160.0620 5.7 1.7E
-09
 1.7 765.1 C6H11NO4 GHB-glycine 3 
Compound 06 HSST ESI
-
 4.58_402.1151m/z 402.1151 4.6 3.3E
-08
 1.7 219.4 
   
Compound 07 HILIC ESI
-
 2.08_104.0472n 103.0399 2.1 5.7E
-05
 1.5 214.0 C4H8O3 GHB 1 
Compound 08 
HSST ESI
+
 
HILIC ESI
+
 
2.35_248.1496m/z 
7.27_248.1487m/z 
248.1496 
248.1487 
2.3 
7.3 
2.1E
-13
 
2.6E
-14
 
2.7 
2.8 
91.8 
122.4 
C11H21NO5 GHB-Carnitine 3 
Compound 09 HILIC ESI
-
 7.38_301.0034m/z 301.0034 7.4 1.1E
-06
 1.3 73.4 
   
Compound 10 
HILIC ESI
-
 
HILIC ESI
-
 
7.34_205.0624m/z 
7.35_249.0526m/z 
205.0624 
249.0526 
7.3 
7.3 
1.6E
-04
 
4.0E
-05
 
1.2 
1.8 
39.1 
13.6 
  
  
  
   
Compound 11 HSST ESI
-
 1.72_159.0295m/z 159.0295 1.7 4.2E
-10
 1.6 28.0 C6H8O5 
  
Compound 12 HILIC ESI
-
 4.63_210.0442m/z 210.0442 4.6 4.7E
-09
 2.2 22.5 C6H13NO5S 
  
Compound 13 HILIC ESI
-
 5.49_192.9821m/z 192.9821 5.5 1.3E
-04
 1.2 18.3 
   
Compound 14 
HSST ESI
-
 
HSST ESI
+
 
4.57_340.1262n 
4.58_340.1233n 
385.1252 
363.1161 
4.6 
4.6 
4.8E
-06
 
4.8E
-12
 
1.4 
2.7 
13.3 
14.3 
  
  
  
   
Compound 15 HSST ESI
+
 5.65_366.2017m/z 366.2017 5.6 3.8E
-07
 1.6 9.7 
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Compound 16 HILIC ESI
-
 5.49_252.9485m/z 252.9485 5.5 2.3E
-04
 1.1 9.3 
   
Compound 17 HSST ESI
-
 12.12_349.2016m/z 349.2016 12.1 8.8E-03 1.0 6.5 
   
Compound 18 
HSST ESI
-
 
HILIC ESI
-
 
4.17_267.1350m/z 
4.92_267.1357m/z 
267.1350 
267.1357 
4.2 
4.9 
9.3E
-11
 
3.8E
-09
 
2.0 
2.1 
4.3 
6.0 
C13H20N2O4 
C13H20N2O4 
  
   
Compound 19 HSST ESI
-
 0.92_75.0084m/z 75.0084 0.9 1.5E
-08
 1.7 51.5 C2H4O3 Glycolate 1 
Compound 20 HSST ESI
+
 2.94_288.1434m/z 288.1434 2.9 7.1E
-05
 1.8 5.2 C13H21NO6 
  
Compound 21 HILIC ESI
-
 5.44_375.0064m/z 375.0064 5.4 8.9E
-06
 1.5 3.9 
   
Compound 22 HILIC ESI
-
 7.37_307.0561m/z 307.0561 7.4 6.9E
-04
 1.5 3.5 
   
Compound 23 HSST ESI
+
 4.18_268.1419n 269.1497 4.2 1.2E
-08
 2.3 3.4 C13H20N2O4 
  
Compound 24 HILIC ESI
-
 4.07_342.0328m/z 342.0328 4.1 1.6E
-03
 1.4 3.4 
   
Compound 25 HILIC ESI
+
 3.74_306.0979m/z 306.0979 3.7 1.1E
-02
 1.2 3.1 
   
Compound 26 HILIC ESI
-
 4.63_129.0194m/z 129.0194 4.6 9.9E
-06
 1.7 2.8 C5H6O4 
  
Compound 27 HILIC ESI
+
 1.52_127.0384m/z 127.0384 1.5 9.0E
-03
 1.2 2.6 
   
Compound 28 HILIC ESI
+
 0.74_627.2342m/z 627.2342 0.7 2.8E
-02
 1.1 2.3 
   
Compound 29 HILIC ESI
-
 7.05_184.0375n 413.0914 7.0 2.8E
-05
 1.7 2.2 
   
Compound 30 HILIC ESI
-
 5.56_205.0956n 226.0737 5.6 2.3E
-04
 1.3 2.2 
   
Compound 31 HILIC ESI
-
 6.67_228.1449n 265.0935 6.7 1.1E
-04
 1.5 2.2 
   
Compound 32 HILIC ESI
-
 4.94_182.0133m/z 182.0133 4.9 8.5E
-06
 1.5 2.0 
   
Compound 33 HILIC ESI
+
 8.62_271.1025m/z 271.1025 8.6 2.9E
-03
 1.1 1.9 C10H14N4O5 Histidinyl-Aspartate 2 
Compound 34 HILIC ESI
+
 7.34_118.0598m/z 118.0598 7.3 2.0E
-04
 1.3 1.6 C3H7N3O2 Glycocyamine 2 
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Compound 35 HILIC ESI
+
 4.48_321.0796m/z 321.0796 4.5 4.5E
-02
 1.0 1.5 
   
Compound 36 HILIC ESI
+
 3.98_264.1103n 297.1440 4.0 3.2E
-02
 1.1 1.5 
   
Compound 37 HSST ESI
-
 1.07_119.0346m/z 119.0346 1.1 6.7E
-06
 1.5 1.4 
   
Compound 38 HILIC ESI
+
 8.61_262.1283m/z 262.1283 8.6 3.2E-
04
 1.5 1.4 C10H14N4O5 Succinylcarnitine 2 
Compound 39 HILIC ESI
+
 9.57_225.1218m/z 225.1218 9.6 3.1E
-02
 1.0 1.4 
   
Compound 40 HILIC ESI
+
 7.33_129.0415n 130.0487 7.3 1.6E
-04
 1.3 1.3 C5H7NO3 
  
Compound 41 HILIC ESI
+
 7.34_367.1413m/z 367.1413 7.3 4.3E
-03
 1.1 0.7 
   
Compound 42 HILIC ESI
+
 7.69_169.1328m/z 169.1328 7.7 6.6E
-06
 1.3 0.6 
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Fig. 1: Metabolism of GHB via different metabolic pathways: oxidation to succinic semialdehyde 
(SSA), α- and β-oxidation to 2,4-dihydroxybutyryl-CoA and 3,4-dihydroxybutyryl-CoA, respectively 
and phase II conjugation to GHB-glucuronide and GHB-sulfate.  
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Fig. 2: Blox plots for GHB, GHB glucuronide and GHB sulfate. Depicted are analyte peak area to 
creatinine ratios for placebo and GHB group (n=19 each). Statistical comparison was performed using 
a paired t-test (p < 0.05): * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 
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Fig. 3: QTOF MS/MS spectra (collision energy 35 eV, collision energy spread +/- 15 eV) used for 
identification of significantly changed features. Given are accurate fragment masses of the respective 
protonated or deprotonated molecular ions, the calculated sum formula of each fragment and 
corresponding ppm deviation. 
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Fig. 4: Blox plots for selected compounds representing typically observed changes between placebo 
and GHB intake. Depicted are analyte peak area to creatinine peak area ratios for placebo and GHB 
group (n=19 each). Statistical comparison was performed using a paired t-test (p < 0.05): * p < 0.05; 
** p < 0.01; *** p < 0.001; **** p < 0.0001 
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Fig. 5: Extracted ion chromatograms for GHB-carnitine (m/z 248. 1492 +/- 10 ppm) of control 
samples (red; negative for GHB tested by immunoassay, n = 20) and GHB positive authentic samples 
(blue; tested positive by immunoassay and GC-MS, n = 10); right part: enlargement to illustrate the 
huge differences between control and authentic samples 
 
 
 
